{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:32:56Z","timestamp":1783521176989,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Fund Project of Guizhou Provincial Health Commission","award":["gzwkj2021-074"],"award-info":[{"award-number":["gzwkj2021-074"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060116"],"award-info":[{"award-number":["82060116"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260129"],"award-info":[{"award-number":["82260129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Support Project of Guizhou Province","award":["[2021] 094"],"award-info":[{"award-number":["[2021] 094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10620-023-08101-1","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T02:01:52Z","timestamp":1694138512000},"page":"4186-4195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor \u03b21\/Smad3 Signaling Pathway"],"prefix":"10.1007","volume":"68","author":[{"given":"Ye-Ting","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Liang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-6834","authenticated-orcid":false,"given":"Wei-Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"4","key":"8101_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.34172\/apb.2020.078","volume":"10","author":"S Adenina","year":"2020","unstructured":"Adenina S, Louisa M, Soetikno V, Arozal W, Wanandi SI. The effect of alpha mangostin on epithelial-mesenchymal transition on human hepatocellular carcinoma HepG2 cells surviving Sorafenib via TGF-beta\/Smad pathways. Adv Pharm Bull 2020;10:648\u2013655.","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"8101_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol 2019;70:151\u2013171.","journal-title":"J Hepatol"},{"issue":"11","key":"8101_CR3","first-page":"737","volume":"9","author":"DA Brenner","year":"2013","unstructured":"Brenner DA. Reversibility of liver fibrosis. Gastroenterol Hepatol 2013;9:737\u2013739.","journal-title":"Gastroenterol Hepatol"},{"key":"8101_CR4","doi-asserted-by":"publisher","first-page":"173982","DOI":"10.1016\/j.ejphar.2021.173982","volume":"898","author":"S Cai","year":"2021","unstructured":"Cai S, Wu L, Yuan S, Liu G, Wang Y, Fang L, Xu D. Carvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway. Eur J Pharmacol 2021;898:173982.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"8101_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0036-1597816","volume":"37","author":"L Campana","year":"2017","unstructured":"Campana L, Iredale JP. Regression of liver fibrosis. Semin Liver Dis 2017;37:1\u201310.","journal-title":"Semin Liver Dis"},{"key":"8101_CR6","doi-asserted-by":"publisher","first-page":"744826","DOI":"10.3389\/fphar.2021.744826","volume":"12","author":"W Chen","year":"2021","unstructured":"Chen W, Zhang J, Zhong W, Liu Y, Lu Y, Zeng Z, Huang H, Wan X, Meng X, Zou F, Cai S, Dong H. Anlotinib inhibits PFKFB3-driven glycolysis in myofibroblasts to reverse pulmonary fibrosis. Front Pharmacol 2021;12:744826.","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"8101_CR7","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/S0168-8278(02)00429-4","volume":"38","author":"SL Friedman","year":"2003","unstructured":"Friedman SL. Liver fibrosis\u2014from bench to bedside. J Hepatol 2003;38:S38\u2013S53.","journal-title":"J Hepatol"},{"issue":"4","key":"8101_CR8","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1016\/j.bbrc.2018.08.098","volume":"503","author":"C He","year":"2018","unstructured":"He C, Wu T, Hao Y. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway. Biochem Bioph Res Co 2018;503:3093\u20133099.","journal-title":"Biochem Bioph Res Co"},{"key":"8101_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","volume":"121","author":"T Higashi","year":"2017","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliver Rev 2017;121:27\u201342.","journal-title":"Adv Drug Deliver Rev"},{"issue":"2","key":"8101_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.31301","volume":"72","author":"F Lei","year":"2020","unstructured":"Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, Zhang XJ, Cai J, Lin L, Ouyang S, Wang X, Yang C, Cheng X, Liu W, Li H, Xie J, Wu B, Luo H, Xiao F, Chen J, Tao L, Cheng G, She ZG, Zhou J, Wang H, Lin J, Luo P, Fu S, Zhou J, Ye P, Xiao B, Mao W, Liu L, Yan Y, Liu L, Chen G, Li H, Huang X, Zhang BH, Yuan Y. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology 2020;72:389\u2013398.","journal-title":"Hepatology"},{"key":"8101_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ddr.22019","volume":"84","author":"J Lei","year":"2022","unstructured":"Lei J, Li Q, Xu H, Luo M, Liu Z, Xiang D, Chen P. Anlotinib improves bile duct ligature-induced liver fibrosis in rats via antiangiogenesis regulated by VEGFR2\/mTOR pathway. Drug Develop Res. 2022;84:143\u2013155.","journal-title":"Drug Develop Res."},{"issue":"Supplement 2","key":"8101_CR12","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1093\/annonc\/mdz072.010","volume":"30","author":"L Liang","year":"2019","unstructured":"Liang L, Hui K, Hu C, Wen Y, Jiang X. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\/STAT3\/VEGFA signaling in non-small cell lung cancer cells. Ann Oncol 2019;30:ii4.","journal-title":"Ann Oncol"},{"issue":"12","key":"8101_CR13","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1042\/CS20190249","volume":"133","author":"F Liu","year":"2019","unstructured":"Liu F, Bayliss G, Zhuang S. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases. Clin Sci 2019;133:1309\u20131320.","journal-title":"Clin Sci"},{"key":"8101_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1146\/annurev.pharmtox.45.120403.095906","volume":"45","author":"S Lotersztajn","year":"2005","unstructured":"Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol 2005;45:605\u2013628.","journal-title":"Annu Rev Pharmacol"},{"key":"8101_CR15","doi-asserted-by":"publisher","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 2017;3:17074.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"8101_CR16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/gutjnl-2019-318372","volume":"69","author":"A Marti-Rodrigo","year":"2020","unstructured":"Marti-Rodrigo A, Alegre F, Moragrega AB, Garcia-Garcia F, Marti-Rodrigo P, Fernandez-Iglesias A, Gracia-Sancho J, Apostolova N, Esplugues JV, Blas-Garcia A. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells. Gut 2020;69:920\u2013932.","journal-title":"Gut"},{"issue":"3","key":"8101_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1055\/s-2001-17554","volume":"21","author":"M Pinzani","year":"2001","unstructured":"Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397\u2013416.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"8101_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jep.2006.06.012","volume":"109","author":"S Raja","year":"2007","unstructured":"Raja S, Ahamed KF, Kumar V, Mukherjee K, Bandyopadhyay A, Mukherjee PK. Antioxidant effect of Cytisus scoparius against carbon tetrachloride treated liver injury in rats. J Ethnopharmacol 2007;109:41\u201347.","journal-title":"J Ethnopharmacol"},{"issue":"22","key":"8101_CR19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New Engl J Med 2014;370:2071\u20132082.","journal-title":"New Engl J Med"},{"issue":"1","key":"8101_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/jphp.13183","volume":"72","author":"H Ruan","year":"2020","unstructured":"Ruan H, Lv Z, Liu S, Zhang L, Huang K, Gao S, Gan W, Liu X, Zhang S, Helian K, Li X, Zhou H, Yang C. Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-beta1 signalling pathway. J Pharm Pharmacol 2020;72:44\u201355.","journal-title":"J Pharm Pharmacol"},{"key":"8101_CR21","doi-asserted-by":"publisher","first-page":"107798","DOI":"10.1016\/j.pharmthera.2020.107798","volume":"222","author":"P Spagnolo","year":"2021","unstructured":"Spagnolo P, Kropski JA, Jones MG, Lee JS, Rossi G, Karampitsakos T, Maher TM, Tzouvelekis A, Ryerson CJ. Idiopathic pulmonary fibrosis: disease mechanisms and drug development. Pharmacol Therapeut 2021;222:107798.","journal-title":"Pharmacol Therapeut"},{"issue":"Suppl 1","key":"8101_CR22","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.clinre.2015.06.015","volume":"39","author":"M Sun","year":"2015","unstructured":"Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gas 2015;39:S60\u2013S63.","journal-title":"Clin Res Hepatol Gas"},{"issue":"1","key":"8101_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C, Chi Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol 2016;9:105.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"8101_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY. Anlotinib: first global approval. Drugs 2018;78:1057\u20131062.","journal-title":"Drugs"},{"issue":"1","key":"8101_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/IGC.0000000000001129","volume":"28","author":"S Taurin","year":"2018","unstructured":"Taurin S, Yang CH, Reyes M, Cho S, Coombs DM, Jarboe EA, Werner TL, Peterson CM, Janat-Amsbury MM. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. Int J Gynecol Cancer 2018;28:152\u2013160.","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"8101_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastro Hepat 2017;14:397\u2013411.","journal-title":"Nat Rev Gastro Hepat"},{"issue":"2","key":"8101_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1515\/reveh-2020-0048","volume":"36","author":"V Unsal","year":"2021","unstructured":"Unsal V, Cicek M, Sabancilar I. Toxicity of carbon tetrachloride, free radicals and role of antioxidants. Rev Environ Health 2021;36:279\u2013295.","journal-title":"Rev Environ Health"},{"issue":"12","key":"8101_CR28","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.3390\/ijms18122537","volume":"18","author":"A Vallee","year":"2017","unstructured":"Vallee A, Lecarpentier Y, Vallee JN. Thermodynamic aspects and reprogramming cellular energy metabolism during the fibrosis process. Int J Mol Sci 2017;18:2537.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"8101_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.113.208223","volume":"349","author":"L Wollin","year":"2014","unstructured":"Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209\u2013220.","journal-title":"J Pharmacol Exp Ther"},{"key":"8101_CR30","doi-asserted-by":"publisher","first-page":"4484211","DOI":"10.1155\/2022\/4484211","volume":"2022","author":"X Xia","year":"2022","unstructured":"Xia X, Pi W, Lan Y, Wu X, Lv D, Meng Y, Yang H, Wang W. Synergistic antitumor effects of anlotinib combined with oral 5-fluorouracil\/S-1 via inhibiting Src\/AKT signaling pathway in small-cell lung cancer. Anal Cell Pathol 2022;2022:4484211.","journal-title":"Anal Cell Pathol"},{"issue":"4","key":"8101_CR31","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 2018;109:1207\u20131219.","journal-title":"Cancer Sci"},{"key":"8101_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2020.07.012","volume":"126","author":"YR Yang","year":"2020","unstructured":"Yang YR, Bu FT, Yang Y, Li H, Huang C, Meng XM, Zhang L, Lv XW, Li J. LEFTY2 alleviates hepatic stellate cell activation and liver fibrosis by regulating the TGF-beta1\/Smad3 pathway. Mol Immunol 2020;126:31\u201339.","journal-title":"Mol Immunol"},{"issue":"1","key":"8101_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.toxlet.2013.06.240","volume":"222","author":"Q Yao","year":"2013","unstructured":"Yao Q, Lin Y, Li X, Shen X, Wang J, Tu C. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis. Toxicol Lett 2013;222:72\u201382.","journal-title":"Toxicol Lett"},{"issue":"4","key":"8101_CR34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4149\/neo_2022_211012N1441","volume":"69","author":"M Yuan","year":"2022","unstructured":"Yuan M, Guo XL, Chen JH, He Y, Liu ZQ, Zhang HP, Ren J, Xu Q. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING\/IFN-beta pathway. Neoplasma 2022;69:807\u2013819.","journal-title":"Neoplasma"},{"key":"8101_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biochi.2014.10.013","volume":"108","author":"L Zhan","year":"2015","unstructured":"Zhan L, Huang C, Meng XM, Song Y, Wu XQ, Yang Y, Li J. Hypoxia-inducible factor-1alpha in hepatic fibrosis: a promising therapeutic target. Biochimie 2015;108:1\u20137.","journal-title":"Biochimie"},{"issue":"1","key":"8101_CR36","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1038\/s41598-017-04317-0","volume":"7","author":"XK Zhao","year":"2017","unstructured":"Zhao XK, Yu L, Cheng ML, Che P, Lu YY, Zhang Q, Mu M, Li H, Zhu LL, Zhu JJ, Hu M, Li P, Liang YD, Luo XH, Cheng YJ, Xu ZX, Ding Q. Focal adhesion kinase regulates hepatic stellate cell activation and liver fibrosis. Sci Rep-UK 2017;7:4032.","journal-title":"Sci Rep-UK"},{"issue":"23","key":"8101_CR37","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.3748\/wjg.v20.i23.7312","volume":"20","author":"WC Zhou","year":"2014","unstructured":"Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroentero 2014;20:7312\u20137324.","journal-title":"World J Gastroentero"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08101-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:09:39Z","timestamp":1697108979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08101-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8101"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08101-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"4 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments involving animals should obtain relevant ethics approval in accordance with national and institutional guidelines prior to commencing any animal work. This study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the ethics committee of Guizhou Medical University, Guizhou, China. The animal experimental ethical number is 2000732.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}